Immunomodulatory peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-16 and is reviewed periodically as new material appears.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
The classic symptoms of diabetes are frequent urination (polyuria), increased thirst (polydipsia), increased hunger (polyphagia), and weight loss. Other symptoms may include blurred vision, itchiness, peripheral neuropathy, recurrent vaginal infections, and fatigue, as well as loss of taste. Many people, however, have no symptoms during the first few years and are diagnosed on routine testing. A small number of people with type 2 diabetes can develop a hyperosmolar hyperglycemic state (a condition of very high blood sugar associated with a decreased level of consciousness and low blood pressure).
Arranging a secret deal in which Tippett would be traded to a club of his choice at the end of 2012 Direct payments of $100,000 outside the salary cap in each of 2011 and 2012 Illegally arranging third-party deals in 2011 and 2012, resulting in Tippett receiving further money outside the salary cap in those years. Adelaide was considered likely to incur a loss of draft picks, among other penalties, if found guilty, but the AFL Commission was yet to complete its hearing into the matter when the National Draft was held on 22 November 2012, so the club was permitted to participate in the draft as normal. However, on the day before the draft, the club voluntarily relinquished its highest two remaining selections (No. 20 and 54) as a "gesture of goodwill" ahead of the hearing. The final hearing took place on 30 November, and Adelaide and Tippett pleaded guilty to all charges. Adelaide was stripped of its first and second round draft picks, and banned from taking any father-son selections, in the 2013 National Draft, and received a $300,000 fine. Tippett was suspended for the 2013 NAB Cup and 11 premiership matches, with a further suspended sentence of 11 matches, and received a $50,000 fine. Several senior Adelaide personnel were also punished by the league: chief executive Steven Trigg and former football manager John Reid were each fined $50,000 and banned from AFL functions for six months (with a further suspended sentence of six months), and current football manager Phil Harper was banned from AFL functions for two months with a four-month suspended sentence.
Hybrid solution- and immobilization-based strategies have been applied, in which ligands functionalized with an enrichment tag, such as biotin, are allowed to float freely in solution and find their target proteins. After an incubation period, ligand-protein complexes can be reacted with streptavidin-coated beads, which bind the biotin tag and allow for pull-down and identification of interaction partners. This technology can be extended to assist with preparation of samples for ABPP and photoaffinity labeling. While immobilization approaches have been reproducible and successful, it is impossible to avoid the limitation of immobilization-induced steric hindrance, which interferes with induced fit. Another drawback is non-specific adsorption of both proteins and small molecules to the bead surface, which has the potential to generate false positives.
=== Biosynthesis === α-Bungarotoxin is a peptide, therefore it undergoes the protein synthesis pathway, involving transcription and translation. The specific genes encoding for the protein are transcribed into mRNA, which is then translated via the ribosomes, leading to the synthesis of the prepropeptide. Lastly, post-translational modification and folding occur. The mature peptide is stored in the venom gland until envenomation when it gets released.
== Threats == Predation on egg cases is thought to be a major source of mortality for developing oviparous sharks, skates and chimaeras. In general, predation is the leading cause of mortality for marine fish eggs, due to their abundance and high nutritional value. Parental care ends when the egg case is released from the body, so the embryo relies on its tough, leathery exterior as its only source of protection. Some gastropods are known to feed on egg cases by boring into the exterior. Sharks are also common predators of egg cases.
Sources: en.wikipedia.org
=== Medical imaging === Ultrasound imaging can be used to evaluate tissue strain, as well as other mechanical properties. Ultrasound-based techniques are becoming more popular because of its affordability, safety, and speed. Ultrasound can be used for imaging tissues, and the sound waves can also provide information about the mechanical state of the tissue.
For a given total heat output, reducing waste volume increases heat density; the space required in a repository also depends on the host rock and its temperature limits. Radioactivity is not the same as the dose potentially received from a waste repository. A 2023 DOE assessment noted that waste radiotoxicity is strongly linked to actinide content, while mobile, long-lived fission and activation products can be important contributors to repository dose. Under typical repository conditions, actinides move more slowly than these products. In principle, breeder fuel cycles can recycle and consume all actinides, leaving only fission products. The table illustrates the gap between medium-lived and long-lived fission products. A 2015 measurement put the half-life of samarium-151, one of the medium-lived fission products, at 94.6±0.6 years. As a result of this physical oddity, after several hundred years in storage, the activity of the radioactive waste from an FBR would quickly drop to the low level of the long-lived fission products. However, to obtain this benefit requires the highly efficient separation of transuranics from spent fuel. If the fuel reprocessing methods used leave a large fraction of the transuranics in the final waste stream, this advantage would be greatly reduced. The FBR's fast neutrons can fission actinide nuclei with even numbers of both protons and neutrons. Such nuclei usually lack the low-speed "thermal neutron" resonances of fissile fuels used in LWRs. The thorium fuel cycle inherently produces lower levels of heavy actinides.
=== Wild animals === Wildlife species, primarily bats, raccoons, skunks, and foxes, act as reservoir species for different variants of the rabies virus in distinct geographic regions of the United States. This results in the general occurrence of rabies as well as outbreaks in animal populations. Approximately 90% of all reported rabies cases in the US are from wildlife. Injections are too laborious for reaching enough animals to reach herd immunity, so oral rabies vaccines (ORVs) are used instead. ORVs are incorporated into food baits and scattered across the landscape for them to be eaten. When an animal bites into the bait, the packets burst and the vaccine is administered. Current research suggests that if adequate amounts of the vaccine is ingested, immunity to the virus should last for upwards of one year. By immunizing wild or stray animals, ORV programs work to create a buffer zone between the rabies virus and potential contact with humans, pets, or livestock. Landscape features such as large bodies of water and mountains are often used to enhance the effectiveness of the buffer. The effectiveness of ORV campaigns in specific areas is determined through trap-and-release methods. Titer tests are performed on the blood drawn from the sample animals in order to measure rabies antibody levels in the blood. Baits are usually distributed by aircraft to more efficiently cover large, rural regions. In order to place baits more precisely and to minimize human and pet contact with baits, they are distributed by hand in suburban or urban regions.
=== United States === Soy sauce production in the United States began in the Territory of Hawaii in 1905 by Yamajo Soy Co, which by 1909 was renamed the Hawaiian Soy Company Ltd. La Choy started selling hydrolyzed vegetable protein–based soy sauce in 1933. Until the popularization of authentic Chinese cuisine in the 1970s, some Americans pejoratively nicknamed the sauce "beetle juice". This slur's usage had heavily declined by 1976.
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.
The precursor, prothymosin alpha, is encoded by the PTMA gene in humans. The 28-residue peptide corresponds to the N-terminal segment released from that larger protein.
It is produced as a fragment of prothymosin alpha and is present in many tissues. Circulating concentrations are low, which makes routine measurement difficult.